R L Murphy

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Defining the toxicity profile of nevirapine and other antiretroviral drugs
    Robert L Murphy
    Northwestern University, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 34:S15-20. 2003
  2. ncbi request reprint Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapy
    Robert L Murphy
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois, USA
    AIDS 17:S1-3. 2003
  3. ncbi request reprint Switch studies: a review
    R L Murphy
    Northwestern University, Chicago, IL 60611 USA
    HIV Med 3:146-55. 2002
  4. doi request reprint Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy
    Robert L Murphy
    Northwestern University Center for Global Health, Northwestern University, Chicago, Illinois 60611, USA
    AIDS 24:885-90. 2010
  5. ncbi request reprint Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks
    R L Murphy
    HIV Treatment Unit, Northwestern University Medical School, Chicago, Illinois, USA
    Antivir Ther 4:85-7. 1999
  6. ncbi request reprint ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
    R L Murphy
    Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    AIDS 15:F1-9. 2001
  7. ncbi request reprint Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
    R L Murphy
    Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Infect Dis 179:1116-23. 1999
  8. ncbi request reprint Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
    R L Murphy
    Division of Infectious Diseases, Northwestern University Medical School, Illinois, Chicago, IL 60611, USA
    J Infect Dis 179:808-16. 1999
  9. ncbi request reprint Stavudine-based multiple agent combinations: initial studies and ongoing comparative trials
    R L Murphy
    AIDS Treatment Unit, Northwestern University, Chicago, IL 60611, USA
    Antivir Ther 3:69-73. 1998
  10. doi request reprint Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients
    Robert L Murphy
    Northwestern University, Chicago, Illinois, USA
    HIV Clin Trials 9:1-10. 2008

Research Grants

  1. Northwestern University Clinical Trial Unit
    Robert Murphy; Fiscal Year: 2007

Detail Information

Publications47

  1. ncbi request reprint Defining the toxicity profile of nevirapine and other antiretroviral drugs
    Robert L Murphy
    Northwestern University, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 34:S15-20. 2003
    ..These measures may help to identify potential toxicities better and any risk factors that predispose patients to the development of treatment-related side-effects...
  2. ncbi request reprint Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapy
    Robert L Murphy
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois, USA
    AIDS 17:S1-3. 2003
  3. ncbi request reprint Switch studies: a review
    R L Murphy
    Northwestern University, Chicago, IL 60611 USA
    HIV Med 3:146-55. 2002
    ..Resolution of lipodystrophy symptoms has not been demonstrated objectively, perhaps because of insufficient follow-up and/or the role of NRTIs in this syndrome...
  4. doi request reprint Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy
    Robert L Murphy
    Northwestern University Center for Global Health, Northwestern University, Chicago, Illinois 60611, USA
    AIDS 24:885-90. 2010
    ..The protease inhibitor atazanavir has an advantageous lipid profile; we studied its effects on arterial function and other metabolic and inflammatory cardiovascular disease risk factors...
  5. ncbi request reprint Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks
    R L Murphy
    HIV Treatment Unit, Northwestern University Medical School, Chicago, Illinois, USA
    Antivir Ther 4:85-7. 1999
    ..The HIV-1 RNA had decreased to <400 copies/ml in 94% of patients and CD4 cell count had increased by approximately 160 cells/mm3 at 24 weeks. The regimen was well tolerated and merits further study...
  6. ncbi request reprint ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
    R L Murphy
    Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    AIDS 15:F1-9. 2001
    ..The activity and durable suppression of HIV-1 observed in this study is probably attributable to the observed tolerability profile and the achievement of high ABT-378 plasma concentrations...
  7. ncbi request reprint Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
    R L Murphy
    Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Infect Dis 179:1116-23. 1999
    ..Plasma HIV RNA values were </=20 copies/mL in 10 of 17 (58.8%) subjects at 58 weeks or last visit. These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine...
  8. ncbi request reprint Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
    R L Murphy
    Division of Infectious Diseases, Northwestern University Medical School, Illinois, Chicago, IL 60611, USA
    J Infect Dis 179:808-16. 1999
    ..04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy...
  9. ncbi request reprint Stavudine-based multiple agent combinations: initial studies and ongoing comparative trials
    R L Murphy
    AIDS Treatment Unit, Northwestern University, Chicago, IL 60611, USA
    Antivir Ther 3:69-73. 1998
    ..Results of these studies should help to define additional first-line treatment options and strategies for sequencing antiretroviral treatment regimens...
  10. doi request reprint Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients
    Robert L Murphy
    Northwestern University, Chicago, Illinois, USA
    HIV Clin Trials 9:1-10. 2008
    ..Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine and lamivudine long term in antiretroviral-naïve patients...
  11. ncbi request reprint Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results
    Robert L Murphy
    Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    AIDS 17:2603-14. 2003
    ..To compare the efficiency and safety of atazanavir and nelfinavir in antiretroviral-naive patients...
  12. pmc Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial
    David M Asmuth
    Division of Infectious Diseases, University of California Davis Medical School, 4150 V Street, Sacramento, CA 95817 1460, USA
    J Infect Dis 201:1686-96. 2010
    ..To our knowledge, the antiviral activity of pegylated interferon alfa-2a has not been studied in participants with untreated human immunodeficiency virus type 1 (HIV-1) infection but without chronic hepatitis C virus (HCV) infection...
  13. ncbi request reprint Transient viremia in HIV-infected patients and use of plasma preparation tubes
    Valentina Stosor
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Clin Infect Dis 41:1671-4. 2005
    ..We caution clinicians against the routine use of plasma preparation tubes for collection of blood samples for HIV-1 level 1 quantification...
  14. ncbi request reprint Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa
    Babafemi O Taiwo
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cytometry B Clin Cytom 74:S11-8. 2008
    ....
  15. doi request reprint Management of antiretroviral failure and resistance in developing countries
    Claudia Hawkins
    Northwestern University, Chicago, Illinois 60611, USA
    Curr Opin HIV AIDS 4:538-44. 2009
    ..This review focuses on the identification and management of these complex patients in settings with limited antiretroviral drug options and resources...
  16. pmc Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria
    Claudia A Hawkins
    Northwestern University, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 52:228-34. 2009
    ..Patterns and frequency of antiretroviral drug resistance mutations observed in these countries may differ from those in the developed world, where HIV-1 subtype B predominates...
  17. doi request reprint Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals
    Robert L Murphy
    Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Antivir Ther 15:185-92. 2010
    ..Here, we aimed to assess the short-term tolerability and antiviral activity of amdoxovir in combination with reduced and standard doses of zidovudine...
  18. doi request reprint Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting
    Babafemi O Taiwo
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, 645 N Michigan Avenue, Suite 900, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 54:85-92. 2010
    ..To determine the efficacy of patient-selected treatment partners on virologic and adherence outcomes during first-line antiretroviral therapy...
  19. doi request reprint Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV
    Chad J Achenbach
    Feinberg School of Medicine and Center for Global Health, Northwestern University, Chicago, USA
    Adv Ther 27:1-16. 2010
    ..We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues...
  20. doi request reprint Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results
    Babafemi Taiwo
    Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Drugs 70:1629-42. 2010
    ....
  21. ncbi request reprint The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)
    Arlene S Pereira
    Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 186:198-204. 2002
    ..The antiretroviral effect of APV monotherapy was related to APV concentrations...
  22. ncbi request reprint Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA
    C J Achenbach
    Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    HIV Med 6:7-12. 2005
    ..Evaluation of extended treatment interruption (TI) in chronic HIV infection among patients successfully treated with antiretroviral therapy...
  23. ncbi request reprint Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy
    Susan L Koletar
    Division of Infectious Diseases, Ohio State University, Columbus, OH 43210, USA
    Clin Infect Dis 39:1500-6. 2004
    ..Descriptions of the durability and consequences of immune reconstitution in patients who start highly active antiretroviral therapy (HAART) while severely immunosuppressed are limited...
  24. ncbi request reprint Antiretroviral therapy for advanced naïve HIV-infected patients: current status and comparison of two different management strategies
    Robert L Murphy
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA
    J Acquir Immune Defic Syndr 46:S1-2. 2007
  25. ncbi request reprint Reviving protease inhibitors: new data and more options
    Robert L Murphy
    The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    J Acquir Immune Defic Syndr 33:S43-52; quiz S53, S55-6. 2003
  26. doi request reprint Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
    ..The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs...
  27. ncbi request reprint Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial
    Roy M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
    JAMA 296:769-81. 2006
    ..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen...
  28. pmc Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s
    Francesca J Torriani
    Infection Prevention and Clinical Epidemiology Unit, University of California San Diego, 200 West Arbor Drive, MC 8951, San Diego, California 92103, USA
    J Am Coll Cardiol 52:569-76. 2008
    ..This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial...
  29. doi request reprint Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)
    Brigitte Autran
    UPMC Univ Paris 06, UMR_543, France
    AIDS 22:1313-22. 2008
    ..Evaluate immunogenicity and clinical efficacy of two immunization strategies with the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients...
  30. ncbi request reprint Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy
    Douglas A Jabs
    Wilmer Eye Institute, 550 North Broadway, Suite 700, Baltimore, Maryland 21205, USA
    Am J Ophthalmol 133:48-61. 2002
    ..To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART)...
  31. ncbi request reprint A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
    Remko van Leeuwen
    International Antiviral Therapy Evaluation Center, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 17:987-99. 2003
    ..To compare one protease inhibitor (PI)-based and two PI-sparing antiretroviral therapy regimens...
  32. ncbi request reprint The pavia consensus statement
    Paul A Volberding
    University of California, San Francisco, USA
    AIDS 17:S170-9. 2003
  33. ncbi request reprint Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy
    Timothy W Schacker
    Department of Medicine, University of Minnesota, MMC 250, 516 Delaware Street, Minneapolis MN 55455, USA
    J Infect Dis 186:1092-7. 2002
    ....
  34. ncbi request reprint Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
    ..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
  35. ncbi request reprint Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis
    Michael Davidson
    Center for Clinical Trials, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    J Infect Dis 186:1013-8. 2002
    ..87 (P=.12) and respective log mean rates of change per month of -0.08 versus -0.21 (P=.08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads...
  36. ncbi request reprint Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    N Engl J Med 350:1850-61. 2004
    ....
  37. ncbi request reprint Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose
    Lieven J Stuyver
    Pharmasset, Inc, Tucker, GA, USA
    Antivir Ther 9:529-36. 2004
    ..A single 10 mg RVT dose resulted in a viral load drop of 0.61 +/- 0.05 log10 providing evidence that a viral strain with the indicated genotype is susceptible to RVT...
  38. ncbi request reprint Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
    ..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
  39. ncbi request reprint Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection
    Mark A Wainberg
    McGill University AIDS Center, Lady Davis Institute Jewish General Hospital, Montreal, QC, Canada
    Antivir Ther 10:13-28. 2005
    ..The successful development of new NRTIs will depend upon a thorough appreciation of these many and complex issues, not only among those involved in the design of clinical studies, but also those contributing to their review and conduct...
  40. ncbi request reprint Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy
    Douglas A Jabs
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 112:771-9. 2005
    ..To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV)...
  41. ncbi request reprint A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    AIDS 17:691-8. 2003
    ..Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen...
  42. ncbi request reprint The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
    J Michael Kilby
    UAB HIV Outpatient Clinic, University of Alabama at Birmingham, CCB 245A, 908 20th Street South, Birmingham, AL 35294 2050, USA
    AIDS Res Hum Retroviruses 18:685-93. 2002
    ..Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment...
  43. pmc Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
    Frank van Leth
    International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    PLoS Med 1:e19. 2004
    ..We analysed whether lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and efavirenz (EFV)...
  44. pmc Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS
    Asa Ohagen
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Virol 77:12336-45. 2003
    ....
  45. ncbi request reprint Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study
    Charles Hicks
    Duke University Medical Center, Durham, North Carolina, 27710, USA
    AIDS 18:775-9. 2004
    ..Results of long-term therapy with LPV/r-based regimens have not been previously reported. This study describes the 4-year (204-week) safety and antiretroviral activity of LPV/r-based treatment in antiretroviral-naive individuals...
  46. ncbi request reprint Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study
    Rob Roy MacGregor
    Infectious Diseases Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    AIDS Res Hum Retroviruses 21:689-95. 2005
    ..MAC-specific T cell responses apparently develop and persist during DMAC, but are dysfunctional or too infrequent to prevent persistence...
  47. pmc Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned
    Ronald B Reisler
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Acquir Immune Defic Syndr 39:159-66. 2005
    ..To report on the incidence of clinical- and laboratory-defined pancreatitis in HIV-1-infected individuals treated with antiretrovirals (ARVs)...

Research Grants2

  1. Northwestern University Clinical Trial Unit
    Robert Murphy; Fiscal Year: 2007
    ..We expect a seamless transition to the new structure described in this application. ADMINISTRATIVE COMPONENT: ..